[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,872,907
  • Shares Outstanding, K 69,210
  • Annual Sales, $ 350 K
  • Annual Income, $ -72,780 K
  • EBIT $ -83 M
  • EBITDA $ -82 M
  • 60-Month Beta 1.61
  • Price/Sales 8,386.27
  • Price/Cash Flow N/A
  • Price/Book 43.72

Options Overview Details

View History
  • Implied Volatility 66.52% (-1.71%)
  • Historical Volatility 67.72%
  • IV Percentile 1%
  • IV Rank 1.54%
  • IV High 352.51% on 11/20/25
  • IV Low 62.05% on 06/23/26
  • Expected Move (DTE 10) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 225
  • Volume Avg (30-Day) 97
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 1,495
  • Open Int (30-Day) 1,432
  • Expected Range 44.40 to 44.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 1
  • High Estimate $-0.35
  • Low Estimate $-0.35
  • Prior Year $-0.29
  • Growth Rate Est. (year over year) -20.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.94 +78.03%
on 07/15/26
45.90 -3.27%
on 08/07/26
+18.11 (+68.89%)
since 07/10/26
3-Month
20.74 +114.08%
on 05/12/26
45.90 -3.27%
on 08/07/26
+25.32 (+132.70%)
since 05/11/26
52-Week
12.56 +253.50%
on 11/20/25
45.90 -3.27%
on 08/07/26
+29.52 (+198.39%)
since 08/11/25

Most Recent Stories

More News
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial...

PLSE : 44.40 (+6.96%)
Pulse Biosciences Nears Pivotal Trial Completion With Nothing Yet Proven in Revenue

Barchart Research What to Expect from PLSE Earnings PLSE Generated August 5, 2026 Current Price $37.90 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 6.42% Pulse Biosciences Nears Pivotal...

PLSE : 44.40 (+6.96%)
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the...

PLSE : 44.40 (+6.96%)
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study...

PLSE : 44.40 (+6.96%)
This Little-Known Biotech Stock Just Hit a New 5-Year High

Pulse Biosciences (PLSE) just hit a new 5-year high and has strong technical momentum. Shares are up more than 100% over the past 52 weeks. Revenue is projected to surge 652.38% this year and 236.71% next....

PLSE : 44.40 (+6.96%)
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates...

PLSE : 44.40 (+6.96%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee...

PLSE : 44.40 (+6.96%)
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver...

PLSE : 44.40 (+6.96%)
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman...

PLSE : 44.40 (+6.96%)
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan...

PLSE : 44.40 (+6.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications...

See More

Key Turning Points

3rd Resistance Point 50.35
2nd Resistance Point 47.80
1st Resistance Point 46.10
Last Price 44.40
1st Support Level 41.85
2nd Support Level 39.30
3rd Support Level 37.60

See More

52-Week High 45.90
Last Price 44.40
Fibonacci 61.8% 33.16
Fibonacci 50% 29.23
Fibonacci 38.2% 25.30
52-Week Low 12.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.